Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PCDH9 antisense RNA 3 (PCDH9-AS3) is a long non-coding RNA transcribed in the antisense orientation from the PCDH9 gene locus at chromosome 13q21.32. It does not encode a protein. Its sequence and expression are cataloged in major gene databases, but there are currently no established molecular functions or biological pathways clearly attributed to this transcript. The lncRNA is likely "non-exonic," meaning it overlaps intronic regions of the PCDH9 locus. There is currently no evidence for direct involvement in disease or for being a therapeutic target, though regulatory lncRNAs at similar loci sometimes participate in modulating neighboring gene expression—such as protocadherin genes thought to play roles in neural adhesion and signaling. There are no interacting drugs, biomarkers, or specific safety concerns relevant to clinical practice, and PCDH9-AS3 is not a target for current therapies. Notes: - The target is sometimes confused with nearby or similar lncRNAs such as PCDH9-AS2 or PCDH9-AS4. - Existing literature and genomic databases confirm identity but lack deeper functional annotation. If more molecular or pathophysiological detail emerges in future studies, re-evaluation may reveal regulatory or disease associations.
None (no drugs are known to target this lncRNA; mechanisms of action would likely involve RNA-based therapeutic strategies if investigated)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on PCDH9 antisense RNA 3 (PCDH9-AS3).